Menopausal Hormonal Therapy and Cancers

Menopausal Hormonal Therapy and Cancers

  • Prof. Jay Chatterjee — Professor at Brunel University London and Consultant Gynaecological Oncologist and Surgeon, currently serves as Clinical Director of Gynaecological Oncology at Royal Surrey NHS Foundation Trust

Obstetrics & Gynaecology · Oncology

Menopausal hormone therapy (MHT) has a complex relationship with cancer risk, influenced by hormone formulation, route of administration, duration of use and individual risk factors. Understanding the differential effects of estrogen-only and combined estrogen–progestogen therapy on breast, endometrial and ovarian cancers is essential for informed clinical decision-making. Unopposed estrogen increases endometrial cancer risk in women with an intact uterus, while combined therapy is associated with a different breast cancer risk profile. MHT decisions in women with a personal history of cancer require careful assessment of tumour type, hormone sensitivity, recurrence risk and symptom burden. Individualised counselling and multidisciplinary collaboration help guide safe and appropriate treatment choices.